Literature DB >> 1514423

CSF drainage in patients with posterior fossa tumours.

W A Taylor1, N V Todd, S E Leighton.   

Abstract

The management of hydrocephalus secondary to a posterior fossa tumour is controversial. We audited recent practice with a retrospective analysis of 287 consecutive patients undergoing posterior fossa exploration for tumour. 85 shunts and 112 external ventricular drains (EVD) were placed. The overall CNS infection rate in the series was 6%. There was a significantly higher (p less than 0.01) infection rate in patients who had a drainage procedure, and a trend towards higher infection rates in patients with two drainage procedures. Early infection rates with EVDs and shunts were the same (7%). One third of patients with hydrocephalus had pre-operative drainage, a third had per-operative drainage but only a quarter required a permanent shunt. The majority of patients will not require a permanent shunt and where temporary CSF diversion is required EVD is reasonable.

Entities:  

Mesh:

Year:  1992        PMID: 1514423     DOI: 10.1007/bf01400627

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  16 in total

1.  Infections complicating the use of external ventriculostomy.

Authors:  R W Smith; J F Alksne
Journal:  J Neurosurg       Date:  1976-05       Impact factor: 5.115

2.  Temporary external valve drainage in hydrocephalus with increased ventricular fluid pressure. (Experiences with 202 cases). (Experiences with 202 cases).

Authors:  B Pertuiset; R Van Effenterre; Y Horn
Journal:  Acta Neurochir (Wien)       Date:  1976       Impact factor: 2.216

3.  Perioperative external ventricular drainage in obstructive hydrocephalus secondary to infratentorial brain tumours.

Authors:  Z H Rappaport; M N Shalit
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

4.  Treatment of ventriculostomy-related infections.

Authors:  P Gerner-Smidt; E Stenager; C Kock-Jensen
Journal:  Acta Neurochir (Wien)       Date:  1988       Impact factor: 2.216

5.  Hydrocephalus following removal of cerebellar astrocytomas in children.

Authors:  B M Stein; M S Tenner; R A Fraser
Journal:  J Neurosurg       Date:  1972-06       Impact factor: 5.115

6.  Temporary control of cerebrospinal fluid volume and pressure by means of an externalized valve-drainage system.

Authors:  R J White; J G Dakters; D Yashon; M S Albin
Journal:  J Neurosurg       Date:  1969-03       Impact factor: 5.115

7.  The management of obstructive hydrocephalus by the use of external continuous ventricular drainage.

Authors:  M N Shalit; Y Ben Ari; N Eynan
Journal:  Acta Neurochir (Wien)       Date:  1979       Impact factor: 2.216

8.  Pediatric posterior fossa tumors: hazards of the "preoperative" shunt.

Authors:  F Epstein; R Murali
Journal:  Neurosurgery       Date:  1978 Nov-Dec       Impact factor: 4.654

9.  Management of hydrocephalus secondary to posterior fossa tumors.

Authors:  L Albright; D H Reigel
Journal:  J Neurosurg       Date:  1977-01       Impact factor: 5.115

10.  Management of obstructive hydrocephalus secondary to posterior fossa tumors by steroids and subcutaneous ventricular catheter reservoir.

Authors:  U D Schmid; R W Seiler
Journal:  J Neurosurg       Date:  1986-11       Impact factor: 5.115

View more
  10 in total

1.  The role of external ventricular drainage for the management of posterior cranial fossa tumours: a systematic review.

Authors:  Pasquale Anania; Denise Battaglini; Alberto Balestrino; Alessandro D'Andrea; Alessandro Prior; Marco Ceraudo; Diego Criminelli Rossi; Gianluigi Zona; Pietro Fiaschi
Journal:  Neurosurg Rev       Date:  2020-06-03       Impact factor: 3.042

2.  Evaluation of clinical characteristics as indicators for shunt procedure in patients with medulloblastoma: PS210.

Authors:  A Paunović; F Milisavljević; J Bošković
Journal:  Porto Biomed J       Date:  2017-09-01

Review 3.  Hydrocephalus with brain tumors in children.

Authors:  Tai-Tong Wong; Muh-Lii Liang; Hsin-Hung Chen; Feng-Chi Chang
Journal:  Childs Nerv Syst       Date:  2011-09-17       Impact factor: 1.475

4.  Endoscopic third ventriculostomy versus ventriculoperitoneal shunt in the treatment of obstructive hydrocephalus due to posterior fossa tumors in children.

Authors:  Nasser M F El-Ghandour
Journal:  Childs Nerv Syst       Date:  2010-08-25       Impact factor: 1.475

Review 5.  Management of posterior fossa tumors and hydrocephalus in children: a review.

Authors:  Chih-Ta Lin; Jay K Riva-Cambrin
Journal:  Childs Nerv Syst       Date:  2015-09-09       Impact factor: 1.475

6.  Management of Posterior Fossa Tumors in Adults Based on the Predictors of Postoperative Hydrocephalus.

Authors:  Chengda Zhang; Tingbao Zhang; Lingli Ge; Zhengwei Li; Jincao Chen
Journal:  Front Surg       Date:  2022-06-01

7.  Endoscopic third ventriculostomy: the best option in the treatment of persistent hydrocephalus after posterior cranial fossa tumour removal?

Authors:  G Tamburrini; B L Pettorini; L Massimi; M Caldarelli; C Di Rocco
Journal:  Childs Nerv Syst       Date:  2008-09-24       Impact factor: 1.475

8.  Value of precraniotomy shunts in children with posterior fossa tumours.

Authors:  M S Griwan; B S Sharma; R K Mahajan; V K Kak
Journal:  Childs Nerv Syst       Date:  1993-12       Impact factor: 1.475

9.  Characteristics and management of hydrocephalus in adult patients with cerebellar glioblastoma: lessons from a French nationwide series of 118 cases.

Authors:  Luc Bauchet; Jacques Guyotat; Thiébaud Picart; Chloé Dumot; David Meyronet; Johan Pallud; Philippe Metellus; Sonia Zouaoui; François Ducray; Isabelle Pelissou-Guyotat; Moncef Berhouma
Journal:  Neurosurg Rev       Date:  2021-07-01       Impact factor: 3.042

10.  Risk factors for hydrocephalus following fourth ventricle tumor surgery: A retrospective analysis of 121 patients.

Authors:  Tengyun Chen; Yanming Ren; Chenghong Wang; Bowen Huang; Zhigang Lan; Wenke Liu; Yan Ju; Xuhui Hui; Yuekang Zhang
Journal:  PLoS One       Date:  2020-11-17       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.